Trialstirzepatidemethamphetamine use disorderut southwesternphase 2

UT Southwestern registers Phase 2 tirzepatide trial in methamphetamine use disorder

The placebo-controlled study runs 32 weeks with weekly subcutaneous injections and is set to start October 1, 2026.

By Priya Raman · Science Reporter

Sep 23 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07825857 is a randomized, double-blind, placebo-controlled Phase 2 trial of tirzepatide in moderate or severe methamphetamine use disorder, sponsored by University of Texas Southwestern Medical Center.
02It adds to the growing effort to test incretins in addiction, a use patients already ask about off-label.
03The trial is not yet recruiting and is sized for tolerability, safety and preliminary efficacy only, so no efficacy conclusions should be drawn.

From the source

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder
NCT07825857 · PHASE2 · NOT YET RECRUITING · Sponsor: University of Texas Southwestern Medical Center · Conditions: Methamphetamine Use Disorder.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07825857